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Background: For complex diseases like cancer, pooled-analysis of individual data represents a powerful tool to
investigate the joint contribution of genetic, phenotypic and environmental factors to the development of a
disease. Pooled-analysis of epidemiological studies has many advantages over meta-analysis, and preliminary results
may be obtained faster and with lower costs than with prospective consortia.
Design and methods: Based on our experience with the study design of the Melanocortin-1 receptor (MC1R)
gene, SKin cancer and Phenotypic characteristics (M-SKIP) project, we describe the most important steps in
planning and conducting a pooled-analysis of genetic epidemiological studies. We then present the statistical
analysis plan that we are going to apply, giving particular attention to methods of analysis recently proposed to
account for between-study heterogeneity and to explore the joint contribution of genetic, phenotypic and
environmental factors in the development of a disease. Within the M-SKIP project, data on 10,959 skin cancer cases
and 14,785 controls from 31 international investigators were checked for quality and recoded for standardization.
We first proposed to fit the aggregated data with random-effects logistic regression models. However, for the
M-SKIP project, a two-stage analysis will be preferred to overcome the problem regarding the availability of
different study covariates. The joint contribution of MC1R variants and phenotypic characteristics to skin cancer
development will be studied via logic regression modeling.
Discussion: Methodological guidelines to correctly design and conduct pooled-analyses are needed to facilitate
application of such methods, thus providing a better summary of the actual findings on specific fields.
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Since millions of Single Nucleotide Polymorphisms
(SNPs) were identified by the SNP Consortium [1], a
growing number of studies have reported the association
of SNPs in candidate genes with several diseases. How-
ever individual studies of typical size usually have low
statistical power to find true associations given the poly-
genic nature of most common diseases, leaving alone
the various forms of potential interactions between gen-
etic, phenotypic and environmental factors. The advent
of genome-wide association studies allowed genotyping
of hundreds of thousands of SNPs across the genome on
a usually large number of subjects, but information on a
wide spectrum of epidemiological and lifestyle factors
were seldom collected, although the role of these factors
in complex diseases is undoubtedly crucial.
Meta-analysis of genetic epidemiological studies has
been adopted to increase the power of smaller candi-
date gene studies by summarizing results from mul-
tiple studies. However the lack of access to individual
data precludes in-depth investigations, including ana-
lyses of gene-gene and gene-environment interaction,
and appropriate stratified analyses. This may poten-
tially lead to false-positive or false-negative results,
or biased magnitudes of associations, as previously
pointed out [2].
Pooled-analysis of the primary data has been shown
to have critical methodological advantages over meta-
analysis [3,4] and has been applied successfully in the
genetic epidemiology field [4-11]. Pooled-analysis uses
standardized definitions of cases, outcomes and covari-
ates, as well as the same analytical methods, thus limit-
ing potential sources of heterogeneity across different
studies. It also allows investigators to better control for
confounding factors, evaluate alternative genetic models
and estimate the joint effect of multiple genes. Finally,
population-specific effect and gene-gene and gene-
environment interactions may be better assessed using
pooled-analysis [12]. The pooling of data from observa-
tional studies has become more common recently, and
different approaches of data analysis have been applied
[13]. Methodological guidelines to correctly design and
conduct pooled-analyses are needed to facilitate appli-
cation of such methods, thus providing a better sum-
mary of the actual findings on specific fields. Moreover,
the awareness of the potential problems connected
with the establishment of international collaborations
and data pooling might help investigators to avoid or
overcome them.
We describe here our experience with the study design
of an international pooled-analysis on Melanocortin-1
receptor gene, SKin cancer and Phenotypic characteris-
tics (M-SKIP project). In the first part of the paper, we
explain the procedures that were used to identify studiesand to collect and standardize data. In the second part
we describe the statistical analysis plan that we are going
to apply, giving particular attention to methods of ana-
lysis recently proposed to account for between-study
heterogeneity and to explore the joint contribution of
genetic, phenotypic and environmental factors in the de-
velopment of a disease.
The M-SKIP project: rationale and aims
Melanocortin-1-receptor (MC1R, MIM#155555) is one
of the major genes that determine skin pigmentation
and it has been reported to be associated with risk of
melanoma [14], possibly through the determination of
the tanning response of skin to UV radiation [15-17].
However the relationship between some MC1R var-
iants and melanoma also in darkly-pigmented Euro-
pean populations suggests that MC1R signaling may
have an additional role in skin carcinogenesis beyond
the UV-filtering differences between dark and fair
skin [18]. In previous meta-analyses [14,19,20] authors
found evidence of a significant association between
melanoma, red hair and fair skin and the five MC1R
variants R151C, R160W, D294H, D84E and R142H,
and suggested a possible role in melanoma develop-
ment, via non-pigmentary pathways, for I155T and
R163Q variants. However, the specific contribution of
each MC1R variant to melanoma development via
pigmentary and non-pigmentary pathways could not
be evaluated in meta-analyses due to the lack of indi-
vidually joint information on MC1R variants and
phenotypic characteristics.
The aim of the M-SKIP project is therefore to per-
form a pooled-analysis of individual data on sporadic
skin cancer cases and controls with information on
MC1R variants, in order to: 1) assess the association
of MC1R variants with melanoma, basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC); 2) assess
the association between MC1R variants and phenotypic
characteristics, including hair and eye color, skin color,
skin type, common and atypical nevi, freckles, and
solar lentigines; and 3) perform stratified analyses on
MC1R variants and skin cancer by phenotypic charac-
teristics, and evaluate MC1R-phenotype interaction in
skin cancer risk.
Data collection and creation of the standardized
dataset
The identification of data sets and data collection
Published epidemiological studies on MC1R variants,
melanoma, non-melanoma skin cancer (NMSC) and
phenotypic characteristics associated with melanoma
[21,22] were searched until April 2010 in the following
databases: PubMed, ISI Web of Science (Science Cit-
ation Index Expanded) and Embase, using the keywords
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combination with the terms “melanoma”, “basalioma”,
“basal cell carcinoma”, “squamous cell carcinoma”, “skin
cancer”, “hair color”, “skin color”, “skin type”, “eye
color”, “nevi”, “freckles”, and “solar lentigines”, with no
search restriction. The computer search was supplemen-
ted by consulting the bibliographies of the articles and
reviews. We also tried to identify unpublished datasets
by personal communication with participant investiga-
tors, members of the Advisory Committee, and with
attendees of scientific meetings. Unpublished datasets
were evaluated by an internal peer-review process before
inclusion.
We selected papers according to the following inclu-
sion criteria: 1) observational studies on single-primary
sporadic skin cancer cases with information on any
MC1R variant or 2) control series with information on
any MC1R variant and at least one phenotypic character-
istic under study. Permanent exclusion criteria were: 1)
populations selected for MC1R status or for other
genetic factors, 2) studies including only familial and/or
multiple-primary melanoma cases, because we wanted to
study MC1R-melanoma association at a population level,
therefore excluding cases for whom the role of genetics is
probably stronger. In the first step of the project, we also
excluded genome-wide association studies (GWAS), be-
cause their different study design and genotyping method-
ology would significantly increase the heterogeneity of our
data; however GWAS with epidemiological data would be
included in a next step of the project and their results
would be compared with those of classical genetic
epidemiological studies.
The original search provided 748 papers, among
them 111 were considered potentially interesting and
full-text articles were retrieved and evaluated. We
excluded 49 articles for the following reasons: duplicate
populations (N = 20), no data on outcome (case/control
status or any of the studied phenotypic characteristics)
or on MC1R variants (N = 12), case reports, commen-
taries or reviews (N= 6), GWAS (N=6), populations
selected for genetic factors (N = 4) and multiple pri-
mary melanoma cases only (N = 1). The remaining 62
independent studies were considered eligible for inclu-
sion in the pooled-analysis.
For each independent study, we identified the corre-
sponding investigator and retrieved his/her contact in-
formation. Each investigator was invited to join the
M-SKIP project: this required them to sign a partici-
pation form and a document attesting to approval of
the study guidelines, and then to provide their data in
electronic form without restrictions on format. A
detailed list of variables relevant for skin cancer was
provided and, for each available variable in the list,
the authors were required to compile a form with aclear and complete description on how it was col-
lected and coded. Investigators did not send any per-
sonal identifier with data, but only identification
codes. Finally, investigators were asked to send a
signed statement declaring that the original study was
approved by an Ethic Committee and/or that study
subjects provided a written consent to participate in
the original study.
Data collection started in May 2009 and was closed in
December 2010. During this period, 43 investigators
were contacted and invited to share data. Thirty-one
(72%) agreed to participate and provided data on 28,998
subjects, including 13,511 skin cancer cases (10,182 mel-
anomas) and 15,477 controls from 37 independent pub-
lished [19,23-62] and 2 unpublished studies. Both the
unpublished datasets came from investigators who were
originally contacted for their published data and who
had further data of (still) unpublished studies. Among
the 12 non-participant investigators, seven did not reply
to our invitation letter, three were not able to retrieve
the original dataset and two were not interested in the
project. The total number of skin cancer cases and
controls from the 25 independent studies [63-95] of
non-participant investigators was 5,135 and 8,262, re-
spectively. The study design was case–control for 13
studies, control-only for 11 studies, and case-only for
one study.
Quality control, data coding and creation of the
standardized dataset
We inspected the data for completeness and resolved
inconsistencies with the investigator of each study. A
number of subjects were excluded due to the following
reasons: multiple-primary melanoma cases (N = 1596),
missing data on MC1R variants (N = 1081), non-skin
melanoma cases (N= 150), subjects with atypical mole
syndrome and no skin cancer (N = 58), non first-
primary melanoma cases (N= 24), familial melanoma
cases, defined as subjects with two first-degree relatives
or three or more any-degree relatives with melanoma
(N= 25), other reasons including: unknown case/control
status, duplicate subjects, or inappropriate controls
(N= 232).
The following study-related variables were recoded
uniformly: study country, study design, source of con-
trols, application of case–control matching, methods to
define phenotypic characteristics, genotyping method-
ology, whether genotyping was done in the same cen-
ter for cases and controls and was blinded for case/
control status, and DNA source. These variables were
not used to assign a quality score to each study, but
will be taken into account in meta-regression and sen-
sitivity analyses. In addition, the variables listed in
Table 1 were retrieved from each study if available,
Table 1 List of the main variables, number of original studies and related subjects per variable
Variable Studies (%)
N=39
Melanoma cases (%)
n = 7806
NMSC cases (%)
n =3151
Controls (%)
n= 14875
Age 37 (95%) 7761 (99%) 3150 (100%) 14550 (98%)
Gender 39 (100%) 7801 (100%) 3151 (100%) 14853 (100%)
Ethnicity 38 (97%) 6770 (87%) 3142 (100%) 13833 (93%)
Body mass index 8 (21%) 557 (7%) 1380 (44%) 2226 (15%)
Smoking status 6 (15%) 2266 (29%) 419 (13%) 2286 (15%)
Intermittent sun exposure 21 (54%) 4493 (58%) 1266 (40%) 2286 (15%)
Continuous sun exposure 21 (54%) 4909 (62%) 741 (24%) 1938 (13%)
Sunburns 25 (64%) 4210 (54%) 1288 (41%) 2968 (20%)
Artificial UV exposure 16 (41%) 3842 (49%) 298 (9%) 1058 (7%)
Family history of skin cancer 27 (69%) 6660 (85%) 1289 (41%) 3318 (22%)
Family history of cancer other than skin 19 (49%) 4445 (57%) 371 (12%) 1630 (11%)
Melanoma body site 24 (62%) 6271 (80%) NA NA
Melanoma histology 19 (49%) 4868 (62%) NA NA
Breslow thickness 24 (62%) 5907 (76%) NA NA
Hair color 34 (87%) 6841 (88%) 2590 (82%) 11889 (80%)
Eye color 31 (79%) 5990 (77%) 2456 (78%) 10720 (72%)
Skin color 23 (59%) 3517 (45%) 826 (26%) 2963 (20%)
Skin type 31 (79%) 6590 (84%) 1992 (63%) 4540 (31%)
Common nevi 19 (49%) 3817 (49%) 442 (14%) 1181 (8%)
Atypical nevi 11 (28%) 2681 (34%) 642 (20%) 1447 (10%)
Freckles 21 (54%) 4028 (52%) 737 (23%) 2333 (16%)
Solar lentigines 6 (15%) 1419 (18%) 442 (14%) 1088 (7%)
NA= not applicable; NMSC=non melanoma skin cancer.
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and entered in the main database. Finally, data on
MC1R variants were entered for each subject. Quality
controls and data coding were performed independ-
ently by two investigators, and inconsistencies were
solved via consensus.
Some variables were collected in different ways in dif-
ferent studies. We report here as an example the rules
we used to standardize sun exposure variables, in order
to provide suggestions on how to recode variables with
highly heterogeneous assessment among studies.
Intermittent and continuous sun exposure was coded
as hours of exposure per day if the information was
structured in this way. If not, we converted it to hours/
day on a scale of 0 as no exposure and 6 as the max-
imum hours of exposure per day. For example, for data-
sets with four classes of exposure (never, seldom, often,
always), we recoded the classes as 0, 2, 4, 6 hours/day. If
individual sun exposure was collected over different time
periods, we calculated the average exposure weighting
for years of exposure in each time period. Other con-
tinuous variables (i.e. days of exposure per year, averagehours of exposure per year) were converted to hours/day
using the following algorithm:
1) calculate the variable mean on all the study subjects as:
μ ¼
Xn
i¼1 xi=n ð1Þ
where xi is the measure of the continuous variable on
subject i, and n is the study sample size;
2) calculate the average hours of exposure/day (ν) over
all the datasets with the variable coded (or recoded)
in this way as in 1);
3) recode each observation basing on the proportion
xi : μ ¼ x^i : ν as:
x^i ¼ νxi=μ ð2Þ
4) set as 6 (maximum hours of exposure per day) the
value of all calculated values greater than 6.
The assumption underlying this coding was that the
average sun exposure pattern for study subjects was
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will use this variable only for confounding adjustment
and/or effect modifier analyses, the purpose was to re-
group subjects with a similar pattern of sun exposure, al-
though the precise individual amount of sun exposure
could not be estimated.
As a general rule, when a variable (i.e. common nevi
count) was collected into classes, we recoded each class
by using its median. The maximum numbers for open
categories were chosen according to the available M-SKIP
data.Brief description of the collected data and
statistical power
The final dataset was created in June 2011 and included
data on 7,806 melanoma cases, 3,151 NMSC cases
(2,211 BCC, 788 SCC and 152 with both), and 14,875
controls.
Distribution of data according to study country in
which the study was performed is presented in Table 2.
The majority of data came from Europe, especially from
southern European populations. There was no signifi-
cant difference in participation rate according to study
area (Fisher exact test p-value: 0.25).
The main characteristics of the studies included in the
M-SKIP database are described in Table 3. The majority
are case–control studies (54%) with population or healthy
controls and case–control matching. Phenotypic charac-
teristics were frequently assessed by self-administered
questionnaire (41%) or examination by a dermatologist or
research nurse (36%). The majority of studies sequenced
the entire coding region of the MC1R (67%) and used
blood as DNA source (62%).
We calculated that the minimum required sample size to
find a statistically significant association between a MC1R
variant and melanoma assuming a similar association toTable 2 Summary of data included in the M-SKIP project by g
Study area Invited investigators Participant investigat
Africa 1 0 (0)
Asia 3 2 (2)
Australia 4 2 (3)
Northern Europea 8 6 (6)
Central Europeb 6 3 (4)
Southern Europec 9 8 (12)
North America 13 11 (12)
TOTAL 43 d 31d (39)
NMSC=non melanoma skin cancer.
a includes Denmark, Norway, Sweden, The Netherlands, UK.
b includes France, Germany, Poland.
c includes Greece, Italy, Spain.
d one investigator collected data for two different areas (North America and Asia).that observed in our previous meta-analysis [14] (Odds
Ratio (OR)= 1.5) is around 7,500 cases and 7,500 controls
for rare variants (1-2% allele frequency in controls), and
1,400 cases and 1,400 controls for common variants (8-10%
allele frequency in controls), with 90% statistical power.
Sample size for gene-environment interaction analysis was
also calculated with the program POWER, version 3.0 [96].
Considering the study of a simple two-way interaction
between an environmental factor and a rare MC1R variant,
around 5,000 cases and 5,000 controls would be needed to
observe a multiplicative interaction effect of 2.0, arising to
16,000 cases and 16,000 controls to observe a smaller
multiplicative effect of 1.5, both with 90% statistical power.
For common MC1R variants, the same gene-environment
interaction effects of 2.0 and 1.5 could be observed with
around 1,200 cases and 1,200 controls, and with around
3,500 cases and 3,500 controls, respectively. Our sample
size therefore is appropriate for the purpose of the analysis,
and large enough to allow stratified and interaction ana-
lyses, especially to find even small interaction effects with
the most frequent variants, and larger interaction effects for
less common variants.Statistical analysis plan
Appropriateness and representativeness of the collected
data
Comparability of the main study population characteris-
tics and results between studies included and excluded
from the pooled-analysis will be assessed. Funnel plots
to evaluate participation bias will be drawn and Egger’s
test [97] will be performed.
Departure of genotype frequencies of each MC1R vari-
ant from expectation under Hardy-Weinberg equilibrium
will be assessed by Chi Square test among controls for
each study, in order to detect any possible genotyping
error or stratification problem in the datasets.eographical location
ors (studies) Melanoma cases NMSC cases Controls
0 0 0
0 0 345
744 298 290
858 1629 8095
977 639 2398
2,747 0 2263
2,480 585 1484
7808 3151 14875
Table 3 Main characteristics of the included studies
Studies (%)
N=39
Melanoma cases (%)
n = 7806
NMSC cases (%)
n= 3151
Controls (%)
n= 14875
Study design
Case–control 21 (54%) 5092 (65%) 2052 (65%) 6852 (46%)
Case only 11 (28%) 2646 (34%) 0 0
Control only 6 (15%) 0 0 1464 (10%)
Cohort 1 (3%) 68 (1%) 1099 (35%) 6559 (44%)
Source of controls
Hospital 6 (21%) 509 (10%) 1169 (37%) 1847 (12%)
Population or healthya 21 (75%) 4651 (90%) 1982 (63%) 12872 (87%)
Mixed 1 (4%) 0 0 156 (1%)
Case–control matching b
No 10 (45%) 3151 (61%) 1739 (55%) 9578 (71%)
Yes 12 (55%) 2009 (39%) 1412 (45%) 3833 (29%)
Phenotype assessment
Self-administered questionnaire 16 (41%) 2768 (35%) 672 (21%) 1875 (13%)
Examination by an expert 14 (36%) 3970 (51%) 1380 (44%) 4392 (30%)
Instrumental measure 2 (5%) 0 0 222 (1%)
Mixed 5 (13%) 297 (4%) 1099 (35%) 7247 (49%)
No measure 2 (5%) 771 (10%) 0 1139 (8%)
Genotype assessment
Sequencing analysis 26 (67%) 5942 (76%) 1059 (34%) 4813 (32%)
Othersc 13 (33%) 1864 (24%) 2092 (66%) 10062 (68%)
DNA source
Blood 24 (62%) 4645 (60%) 2743 (87%) 13304 (89%)
Buccal cells 14 (36%) 3161 (40%) 408 (13%) 1326 (9%)
Tissue 1 (3%) 0 0 245 (2%)
NMSC=non melanoma skin cancer.
a healthy subjects are blood donors, friends or relatives of cases.
b individual or frequency.
c includes RFLP, SNaPshot, allele discrimination assay.
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models
A first analysis using data combined into one dataset, is
to fit them with logistic regression models with random
slope. Considering a dominant model, let πik/X be the
probability of skin cancer for subject i (i = 1,. . .,nk) of
study k (k = 1,. . .,K) conditional on the presence of a cer-
tain MC1R variant (X). We will account for the fixed
MC1R effect and the random selection of studies, as-
suming a model that relates MC1R and study effects
linearly to the logit of the probabilities:
logit πik=Xð Þ ¼ αþ βXik þ bkXik ð3Þ
In this model the transformed regression coefficient
exp(β) is the odds of skin cancer for a subject withthe MC1R variant compared with a subject without
the MC1R variant, and the bk are the study-specific
coefficients accounting for the random selection of
studies, with bk ~N(0, σ
2
b), where σ
2
b represents the between
study variance of theMC1R effect.
The logistic regression model above described could be
applied to different inheritance models and could include
covariates, in order to adjust the studied associations by
possible confounding factors. In order to include the
available information from all the studies, missing values
could be estimated in the model with multiple imput-
ation and/or the creation of a missing-data indicator
variable. However, when the majority of missing data are
the results of non-availability of certain variables in some
studies, as for the M-SKIP project, the use of both mul-
tiple imputation and the missing-data indicator would be
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complete case method [98,99] and a two-stage approach
would be preferred.
Two-stage analysis with random effects models
The two-stage analysis method [100] will allow us to
overcome the problem of the availability of different
study covariates. The pooled-estimates of the association
of MC1R variants with each skin cancer type and each
phenotypic characteristic will be calculated as follows.
First, study-specific ORs will be calculated by applying
logistic regression to the data from each study to esti-
mate the odds of skin cancer conditional on the pres-
ence of a MC1R variant (X), controlling for confounders
Zk. For study k (k = 1,. . .,K), assuming just one confoun-
der, the model is written as:
logit πik=Xð Þ ¼ αk þ βkXik þ γkZik ð4Þ
where πik is the conditional probability of skin cancer for
subject i (i = 1,. . .,nk) of study k. Although MC1R variants
were uniformly defined across studies, the confounders
Zk may be specific to a particular study. Analyses with
original covariates and with recoded data will be per-
formed and compared. The exposure log-odds ratio for
study k is denoted βk, the confounding log-odds ratio is
denoted γk, and the αk are the study-specific intercepts.
The βk are assumed to vary across studies according to
the second-stage model:
βk ¼ βþ bk þ ek ð5Þ
where β is the pooled-exposure log-odds ratio, bk are ran-
dom effects with bk ~N(0, σ
2
b), where σ
2
b represents the
variability of the study-specific exposure effects βk about
the population mean β, and ek are independent errors with
ek ~N(0, σ
2
k), where σ
2
k describes the within-study variation
of the βk. In the first stage β^kand its variance σ^k2 are esti-
mated from equation 4, separately for each study.
The two-stage estimator of the pooled exposure effect β
is a weighted average of the β^k , weighted by the inverse
marginal variances of the β^k , denoted wk ¼ σ^ 2k þ σb2
 1
.
Thus:
β^ ¼
X
k
wk β^k
 
=
X
k
wk ð6Þ
var β^
 
¼
X
k
wk
 1
ð7Þ
Two methods [100] are frequently used to estimate
the random effects variance σ2b in equations 6 and 7.
These methods are pseudo-maximum likelihood and
moment estimation.Investigation of heterogeneity among studies
Homogeneity among the study estimates will be mea-
sured by Q statistic and I-Square [101], the latter repre-
senting the percentage of total variation across studies
that is attributable to heterogeneity rather than to
chance. Meta-regression analysis will be performed to
investigate heterogeneity among study estimates, by
evaluating the role of methodological characteristics of
the studies and the characteristics of study populations.
Joint association of MC1R and phenotypic characteristics
with skin cancer risk
Stratified analysis for the association of MC1R variants
with each skin cancer type will be performed for differ-
ent phenotypic characteristics. The hypothesis of homo-
geneity of ORs among strata will be verified using the
Breslow-Day test [102].
In order to identify combinations of MC1R variants
and phenotypic characteristics associated with each skin
cancer type, we will perform logic regression, a recently
proposed tree-based statistical method intended for bin-
ary predictors [103]. This approach is particularly useful
for detecting subpopulations at high or low risk of dis-
ease, characterized by high-order interactions among
covariates, and thus the methodology could be well ap-
plied to the study of complex diseases like cancer. First,
we will dichotomize continuous and categorical variables
by choosing appropriate thresholds and by creation of
dummy variables. For phenotypic characteristics we will
define dummy variables in order to 1) have as much dif-
ferentiation as possible in hair and eye color, and 2) sep-
arate the extreme classes of skin type and common nevi
count from intermediate classes, because it has been
suggested [21] that in the meta- and pooled-analysis set-
ting misclassification affects the intermediate classes of
exposure more than the extreme ones. Let X1, X2,. . ., Xp
be the binary predictors obtained by dichotomization,
and let Y be the binary response variable (case/control
status). The appropriate logic regression model can be
written as:
logit Y ¼ 1ð jX1;X2; . . . ;XnÞ ¼ αþ
Xk
j¼1
βjLj ð8Þ
where Lj is a Boolean expression of the predictors Xi,
such as Lj ¼ XC4 ∧ X5∨X1∨XC3
 
with ∧ ¼ AND, ∨ ¼ OR
and C ¼ NOT. Logic regression could be generally applied
to any type of regression outcome as long as the proper
scoring function is specified. For the logic regression
model in equation 8, the goal is to find the Boolean
expressions Lj that minimize the binomial deviance,
with the parameters βj and the Boolean expressions Lj
estimated simultaneously. The output from logic regression
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dictor Lj, and the associated regression coefficient. An ex-
ample of a logic tree that may be applied to our pooled
analysis is shown in Figure 1. Using this representation it is
possible to start from a logic tree and obtain any other logic
tree by a finite number of operations such as growing of
branches, pruning of branches, changing of predictors and/
or operators.
The searching for the optimum combinations of MC1R
variants and phenotypic characteristics mostly associated
with skin cancer will be undertaken by a (stochastic) simu-
lated annealing algorithm [104-106]. This algorithm has a
good chance to find a model that has the best or close to
best possible score but, in the presence of noise in the
data, typically overfits data. In order to select the best
model, application of a combination of cross-validation
and randomization tests has been suggested [104,105].
In an explanatory setting, at risk gene-phenotype com-
binations will be identified among a very large number of
possible combinations by logic regression-based methods
recently proposed [106,107]. The skin cancer risk of the
identified subpopulations will be estimated within the
pooled-analysis context using the two-stage analysis previ-
ously described.
Structural equation models will be also applied to even-
tually clarify the independent and dependent role of MC1R
variants on skin cancer by phenotypic characteristics.
Finally, the role of environmental exposure will be
investigated by entering new covariates in the models,
by subgroup analyses and by studying gene-environment
and phenotype-environment interactions using trad-
itional and new proposed methodologies [108].
Use of MC1R data
In all the proposed analyses, each of the nine most fre-
quently investigated MC1R variants (V60L, D84E,Figure 1 Example of a logic tree representing the Boolean
expression “more than 50 common naevi V [skin type IV Λ
(MC1R R151C V brown hair)]”.V92M, R142H, R151C, I155T, R160W, R163Q, D294H),
as well as known rare mutations affecting MC1R function
[109] will be evaluated assuming different inheritance
models and choosing the one that fits the data best.
Haplotype frequencies will be estimated using the itera-
tive Expectation-Maximization algorithm [110,111], and
their association with each skin cancer type and pheno-
typic characteristics will be evaluated. Moreover, for the
studies that sequenced the entire gene, we will evaluate
the impact on skin cancer and phenotypic characteristics
of the total number of MC1R variant alleles and of the
scores obtained from appropriate classification of MC1R
variants [112].Discussion
Based on our experience with the study design of the
M-SKIP project, we have described here the most im-
portant steps in planning, conducting and analyzing pooled
individual data from genetic epidemiological studies. A
previously published commentary highlighted the advan-
tages and limitations of this kind of analyses, but did not
describe the statistical methods that could be used to pool
datasets [4]. Some methods for pooling results of epi-
demiological studies were suggested [10,100,112-114], but
specific problems related to genetic epidemiology – such
as the evaluation of different genotyping methodology, the
Hardy-Weinberg equilibrium testing, the hereditary model
assumption, and the assessment of gene-phenotype
and gene-environment interaction – were not discussed.
Within the M-SKIP project, we collected a large
amount of data in which multiple hypotheses can be
examined with greater statistical power than is possible
in individual studies. The response rate of invited inves-
tigators was high (72%), probably due to the well defined
criteria of data collection and use, the clear publication
policy, and the presence of an Advisory Committee
tasked with monitoring adherence to project guidelines
and scientific quality. Another strength of the pooled-
analysis here described is the carefully-planned approach
to standardizing the demographic, epidemiological and
phenotypic information obtained from individual stud-
ies, giving the opportunity to perform appropriate and
detailed subgroup and interaction analyses. Because the
inclusion of an individual study in a particular analysis is
not dependent on whether those investigators have pub-
lished findings on that association, and because of
inclusion of unpublished datasets, our pooled-analysis
should not be affected by publication bias, as it might
a meta-analysis of the published literature. Finally, we
plan to analyze data by conventional and recently
proposed statistical methods, and will compare and
integrate the results obtained with these different
approaches.
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http://www.biomedcentral.com/1471-2288/12/116The main limitation of a pooled analysis, especially with
respect to prospective consortia, is that it was planned
retrospectively, and hence there was no a priori
standardization of data collection. On the other hand,
pooled-analysis may be feasible with fewer funds than
those required for a prospective consortium, and it takes
shorter time to obtain results because the original data
have already been collected. The quality of genotype
methodology may be heterogeneous among different par-
ticipant laboratories. We will take into account this pos-
sible problem both by calculation of Hardy-Weinberg
equilibrium and by meta-regression analysis. Finally, while
we will try to assess the existence of participation bias, we
cannot completely rule out that the results could be
affected by the exclusions of the studies from the investi-
gators who refused to participate in this pooled analysis.
In conclusion, the data collected within the M-SKIP
project are a valuable resource for investigating associa-
tions between MC1R variants and skin cancer, particularly
for population subgroups, and may be an appropriate set-
ting to better investigate the genetics of sporadic skin
cancer. A pooled-analysis of epidemiological studies is
feasible, has many advantages over meta-analysis in mak-
ing it possible to adjust for confounders and assess inter-
actions, and in addition preliminary results may be
obtained with lower costs and shorter time than with pro-
spective consortia. We are convinced that its success
depends upon the initial definition and approval of clear
guidelines necessary for conducting such studies. The dif-
fusion of pooled-analysis in genetic epidemiology field
will assist epidemiologists and other health professionals
in synthesizing the vast amount of available data on spe-
cific gene-disease associations and a common data-base
would be the source of possible future investigations.
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